NCCN recognizes Oncotype DX test as the only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In updated guidelines for breast cancer, the National Comprehensive Cancer Network recognized the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with one to three positive axillary lymph nodes, including micro metastases. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login